UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 18,532 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 30.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 80,106 shares of the company's stock after buying an additional 18,532 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.13% of Vera Therapeutics worth $3,388,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Avoro Capital Advisors LLC boosted its stake in shares of Vera Therapeutics by 30.2% in the 4th quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company's stock valued at $237,247,000 after purchasing an additional 1,300,410 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in Vera Therapeutics by 11.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,377,049 shares of the company's stock worth $185,107,000 after purchasing an additional 437,940 shares during the last quarter. FMR LLC lifted its holdings in Vera Therapeutics by 9.6% during the 4th quarter. FMR LLC now owns 3,053,126 shares of the company's stock worth $129,117,000 after buying an additional 267,842 shares during the period. Vanguard Group Inc. grew its position in shares of Vera Therapeutics by 14.3% in the 4th quarter. Vanguard Group Inc. now owns 2,949,564 shares of the company's stock valued at $124,737,000 after buying an additional 369,387 shares during the last quarter. Finally, Paradigm Biocapital Advisors LP increased its stake in shares of Vera Therapeutics by 31.0% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 1,437,339 shares of the company's stock valued at $60,785,000 after buying an additional 340,488 shares during the period. Institutional investors own 99.21% of the company's stock.

Wall Street Analyst Weigh In

VERA has been the subject of several research analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $85.00 price target (up from $75.00) on shares of Vera Therapeutics in a research note on Monday, June 2nd. Wedbush decreased their price objective on Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Cantor Fitzgerald cut their target price on Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. Guggenheim restated a "buy" rating on shares of Vera Therapeutics in a research note on Tuesday, June 3rd. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 4th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $65.00.

Vera Therapeutics Stock Down 25.9%

NASDAQ:VERA traded down $7.93 during trading hours on Friday, hitting $22.70. 12,635,089 shares of the company traded hands, compared to its average volume of 926,133. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. The company has a market cap of $1.45 billion, a PE ratio of -8.70 and a beta of 1.13. The firm's 50-day simple moving average is $22.40 and its 200-day simple moving average is $31.39. Vera Therapeutics, Inc. has a one year low of $18.53 and a one year high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). During the same quarter in the prior year, the company earned ($0.56) EPS. Equities analysts predict that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.